Enanta Pharmaceuticals (ENTA) FCF Margin (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of FCF Margin data on file, last reported at 41.7% in Q1 2026.

• Quarterly FCF Margin rose 10799.0% year-over-year to 41.7% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.98% (up 11287.0% YoY) and the FY2025 annual result came in at 29.5%, up 9523.0% from the prior year.
• FCF Margin climbed to 41.7% in Q1 2026, from 62.85% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 94.74% in Q2 2025 to a low of 202.24% in Q2 2023.
• A 5-year average of 96.09% and a median of 113.38% in 2024 frame the typical range for FCF Margin.
• Annual changes were most pronounced in 2022 — FCF Margin sank 11822 bps — and 2025, when it surged 15754 bps.
• Tracing ENTA's FCF Margin over 5 years: stood at 151.14% in 2022, then climbed by 6 bps to 141.46% in 2023, then climbed by 20 bps to 113.38% in 2024, then jumped by 45 bps to 62.85% in 2025, then surged by 34 bps to 41.7% in 2026.
• The last three FCF Margin figures came in at 41.7% (Q1 2026), 62.85% (Q4 2025), and 32.72% (Q3 2025), per Business Quant data.